Oncology · Chemotherapy SupportRegulatory Approvalcommercialnear-term

Hikma's Leucovorin Calcium ANDA072733 Receives Abbreviated Approval

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Hikma28 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:32:16 PM

Assessment confidence: 62% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Hikma's Abbreviated Approval for Leucovorin Calcium introduces a new competitor in the oncology support market, which could disrupt existing pricing structures and market shares. Pharma strategy teams should closely monitor this development to assess its impact on their portfolios. Regulatory context from FDA (FDA AP — LEUCOVORIN CALCIUM (SUPPL)) supports the near-term read. Assessment grounded in 28 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Hikma's entry on pricing and market share for Leucovorin Calcium products. The strongest clinical anchor is A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov), moderate corpus alignment. In Oncology · Chemotherapy Support, 8 regulatory and 5 competitive items passed relevance filtering for Hikma.

Competitive Pressure

The most relevant competitive pressure comes from Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small (Bristol Myers Squibb) — sponsor/company relevance (bristol myers squibb). Secondary pressure from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis. This approval allows Hikma to enter the market for Leucovorin Calcium,

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEUCOVORIN CALCIUM (SUPPL) (FDA). Entity match (hikma); Regulatory pathway relevance (nda). The approval is an Abbreviated Approval, indicating that regulatory compliance has been met without significant new requirements.

Key Opportunities

The entry of Hikma into the Leucovorin Calcium market may lead to increased competition, potentially affecting pricing and market share for current suppliers.
Upside for Hikma may improve if A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Hikma may improve if Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · Immune-Mobilizing T-cell Receptors · Regulatory Approval · The approval of tebentafusp positions it as a key player in the uveal melanoma market, potentially impacting competitors developing similar therapies.
Portfolio teams should assess the impact of Hikma's entry on pricing and market share for Leucovorin Calcium products.

What Would Change This Assessment

This becomes more urgent if Monitor Hikma's launch timeline and market uptake of Leucovorin Calcium.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Entity match (hikma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma
Humanexa Signalsmedium relevance
Moderate corpus alignment

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Development and Preliminary Clinical Evaluation of Multifunctional Operative Support Arm in Reproductive Laparoscopic Surgery: A Randomized Controlled Study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Neoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison FT-IR spectral fingerprints of kidney Cancer in urine and serum: Clinical correlations and diagnostic potential.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hikma

Commercial impact

medium

The entry of Hikma into the Leucovorin Calcium market may lead to increased competition, potentially affecting pricing and market share for current suppliers.

Regulatory impact

low

The approval is an Abbreviated Approval, indicating that regulatory compliance has been met without significant new requirements.

What to watch

Monitor Hikma's launch timeline and market uptake of Leucovorin Calcium.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.